ZNF213-AS1: A Potential Drug Target and Biomarker (G100507458)

ZNF213-AS1: A Potential Drug Target and Biomarker

Zinc finger nucleosome (ZFN) proteins are a family of proteins that play a crucial role in chromatin structure and function. ZNF213-AS1, a member of this family, has been identified as a potential drug target and biomarker for various diseases, including cancer. In this article, we will explore the structure and function of ZNF213-AS1, and discuss its potential as a drug target and biomarker.

Structure and Function

ZNF213-AS1 is a 213-kDa protein that contains a zinc finger domain and a N-terminal transmembrane domain. The zinc finger domain is a common structural feature that consists of four conserved amino acids: ZNF213-AS1, ZNF214, ZNF215, and ZNF216. This domain plays a critical role in protein-protein interactions and is involved in the regulation of various cellular processes, including cell growth, differentiation, and inflammation.

The N-terminal transmembrane domain of ZNF213-AS1 is responsible for the protein's localization to the end of the cell membrane and is involved in the regulation of its intracellular distribution. This domain is known to be involved in various signaling pathways, including the TGF-β pathway and the PI3K/Akt signaling pathway.

Expression and Localization

ZNF213-AS1 is expressed in various tissues and organs, including brain, heart, liver, and pancreas. It is also expressed in various cell types, including epithelial cells, immune cells, and cancer cells. ZNF213-AS1 is predominantly expressed in the nuclei of these cells and is localized to the nuclear envelope, where it is involved in the regulation of various cellular processes, including DNA replication, transcription, and translation.

In addition to its localization to the nuclear envelope, ZNF213-AS1 is also known to be involved in the regulation of cellular processes that are not limited to the nucleus. For example, it has been shown to be involved in the regulation of mitochondrial function, cellular adhesion, and the regulation of inflammation.

Potential Drug Target

ZNF213-AS1 has been identified as a potential drug target due to its unique structure and function. One of its potential drug targets is the regulation of cellular processes that are affected by the TGF-β pathway, which is a well-established target for many diseases, including cancer.

The TGF-β pathway is involved in the regulation of cellular processes that are critical for cell growth, differentiation, and survival. It is a complex signaling pathway that is involved in the regulation of various cellular processes, including cell proliferation, migration, and angiogenesis.

Disruptions in the TGF-β pathway have been implicated in the development and progression of many diseases, including cancer. Therefore, targeting this pathway with drugs that can inhibit its activity could be an effective strategy for the treatment of these diseases.

In addition to its potential role in the TGF-β pathway, ZNF213-AS1 has also been shown to be involved in the regulation of cellular processes that are not related to the TGF-β pathway. For example, it has been shown to be involved in the regulation of mitochondrial function, cellular adhesion, and the regulation of inflammation.

Biomarker Potential

ZNF213-AS1 has also been identified as a potential biomarker for several diseases, including cancer. Its potential as a biomarker is based on its expression and localization to the nuclei of various cell types, as well as its involvement in the regulation of cellular processes that are critical for disease progression.

The detection and quantification of ZNF213-AS1 expression is an important step in the development of biomarkers for cancer. Several techniques, including qRT-PCR, have been developed to measure the expression of ZNF213-AS1 in various tissues and

Protein Name: ZNF213 Antisense RNA 1 (head To Head)

The "ZNF213-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF213-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ZNF214 | ZNF215 | ZNF217 | ZNF219 | ZNF22 | ZNF22-AS1 | ZNF221 | ZNF222 | ZNF223 | ZNF224 | ZNF225 | ZNF225-AS1 | ZNF226 | ZNF227 | ZNF229 | ZNF23 | ZNF230 | ZNF232 | ZNF232-AS1 | ZNF233 | ZNF234 | ZNF235 | ZNF236 | ZNF236-DT | ZNF239 | ZNF24 | ZNF248 | ZNF25 | ZNF250 | ZNF251 | ZNF252P | ZNF252P-AS1 | ZNF253 | ZNF254 | ZNF256 | ZNF257 | ZNF26 | ZNF260 | ZNF263 | ZNF264 | ZNF266 | ZNF267 | ZNF268 | ZNF271P | ZNF273 | ZNF274 | ZNF275 | ZNF276 | ZNF277 | ZNF28 | ZNF280A | ZNF280B | ZNF280C | ZNF280D | ZNF281 | ZNF282 | ZNF283 | ZNF284 | ZNF285 | ZNF285CP | ZNF286A | ZNF286B | ZNF287 | ZNF292 | ZNF295-AS1 | ZNF296 | ZNF3 | ZNF30 | ZNF300 | ZNF300P1 | ZNF302 | ZNF304 | ZNF311 | ZNF316 | ZNF317 | ZNF318 | ZNF319 | ZNF32 | ZNF32-AS1 | ZNF32-AS2 | ZNF32-AS3 | ZNF320 | ZNF321P | ZNF322 | ZNF322P1 | ZNF324 | ZNF324B | ZNF326 | ZNF329 | ZNF330 | ZNF331 | ZNF333 | ZNF334 | ZNF335 | ZNF337 | ZNF33A | ZNF33B | ZNF33BP1 | ZNF34 | ZNF341